SciClone Pharmaceuticals (SCLN) Announces 2-Year $20 Million Buyback Plan, Reaffirms FY11 Guidance
Tweet
Share
E-mailGet Alerts SCLN Hot Sheet
Price: $11.15 --0%
Financial Fact:
Other (expense) income, net: 451K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Other (expense) income, net: 451K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that its Board of Directors has approved a share repurchase program that authorizes the company to repurchase up to $20 million of its outstanding common stock over the next 24 months.
In addition, SciClone reaffirmed its previously announced 2011 financial guidance with the understanding that any cash used to repurchase shares may decrease the year-end cash balance and that a reduction in shares outstanding may increase fourth quarter and full year earnings per share.
In addition, SciClone reaffirmed its previously announced 2011 financial guidance with the understanding that any cash used to repurchase shares may decrease the year-end cash balance and that a reduction in shares outstanding may increase fourth quarter and full year earnings per share.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is the global equity rally broadening? UBS weighs in
- Advance Auto Parts (AAP) PT Lowered to $43 at Truist Securities
- Zurn Water Solutions (ZWS) Reiterated at Buy by Stifel on New Product Development Momentum
Create E-mail Alert Related Categories
Guidance, Stock BuybacksRelated Entities
Stock Buyback, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
